Inhibition of glycogen synthase kinase-3β promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines

Journal of Cellular Biochemistry

Volumn 109, Issue 6, 2010, Pages 1192-1200

  Schütz, Stefanie V ^a   Cronauer, Marcus V ^a   Rinnab, Ludwig ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Androgen receptor; CRM1; GSK 3B; Nuclear export

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ANDROGEN RECEPTOR; ANDROSTANOLONE; GLYCOGEN SYNTHASE KINASE 3BETA;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FATTY ACIDS, UNSATURATED; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOPRECIPITATION; KARYOPHERINS; MALE; MICROSCOPY, FLUORESCENCE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 77951717947     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22500     Document Type: Article

References (50)

1. Cronauer MV, Schulz WA, Burchardt T, Anastasiasidis AG, De La Taille A, Ackermann R, Burchardt M. 2003. The androgen receptor in hormone refractory prostate cancer: Relevance of different mechanisms of androgen receptor signaling. Int J Oncol 23:1095-1102.
2. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. 2004. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23: 3541-3549. (Pubitemid 38658420)
3. Cronauer MV, Ince Y, Engers R, Suschek C, Weidemann W, Burchardt M, Siess H, Ackermann R, Kröncke K-D. 2007. Nitric oxide-mediated inhibition of androgen receptor activity: Possible implications for prostate cancer progression. Oncogene 26:1875-1884. (Pubitemid 46474631)
4. de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, Stewart S, Gumerlock PH. 1997. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 31(1): 1-6. (Pubitemid 27058095)
5. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1): 34-45.
6. Freedman ND, Yamamoto KR. 2004. Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol Biol Cell 15(5): 2276-2286.
7. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. 2002. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277(32): 29304-29314.
8. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. 1998. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58(24): 5718-5724. (Pubitemid 29006412)
9. Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. 2001. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898. (Pubitemid 32691931)
10. Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D. 2007. Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol 21(10): 2427-2439. (Pubitemid 47529356)
11. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y. 2006. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10(4): 309-319. (Pubitemid 44512189)
12. Hartel A, Didier A, Pfaz MW, Meyer HH. 2003. Characterisation of gene expression patterns in 22Rv1 cells for determination of environmental androgenic/antiandrogenic compounds. J Steroid Biochem Mol Biol 84: 231-238. (Pubitemid 36519202)
13. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. 1995. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55(14): 3068-3072.
14. Itoh M, Adachi H, Yasui H, Takekawa M, Tanaka H, Imai K. 2002. Nuclear receptor export of glucocorticoid receptor is mediated by enhanced c-JUN N-terminal Kinase-mediated phosphorylation. Mol Endocrinol 16(19): 2382-2392. (Pubitemid 35155548)
15. Jenster G, van der Korput JA, Trapman J, Brinkmann AO. 1992. Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol 41(3-8): 671-675.
16. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S. 1999. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 96(16): 9112-9117. (Pubitemid 29374716)
17. Kumar AS, Naruszewicz I, Wang P, Leung-Hagesteijn C, Hannigan GE. 2004. ILKAP regulates ILK signaling and inhibits anchorage-independent growth. Oncogene 23:3454-3461.
18. Liao X, Zhang L, Thrasher JB, Du J, Li B. 2003. Glycogen synthase kinase 3β suppression iliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2: 1215-1222.
19. Liao X, Thrasher JB, Holzbeierlein JB, Stanely S, Li B. 2004. Glycogen synthase kinase-3 beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145:2941-2949.
20. Liu J, DeFranco DB. 2000. Protracted nuclear export of glucocorticoid receptor limits its turnover and does not require the exportin 1/CRM1-directed nuclear export pathway. Mol Endocrinol 14(1): 40-51.
21. Liu S, Vinall RL, Tepper C, Shi X-B, Xue LR, Ma A-H, Wang L-Y, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung H-J. 2008. Inappropriate activation of androgen receptor by relaxin via β-catenin pathway. Oncogene 27:499-505.
22. Lochhead P, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. 2006. A chaperone-dependent GSK3β transitional intermediate mediates activation-loop autophoshorylation. Mol Cell 24:627-633.
23. Lombardi M, Castoria G, Migliaccio A, Barone MV, Di Stasio R, Ciociola A, Bottero D, Yamaguchi H, Appella E, Auricchio F. 2008. Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells. J Cell Biol 182(2): 327-340.
24. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM. 2004. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 23(47): 7882-7892.
25. McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J. 2008. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 98(6): 1094-1101.
26. Meares GP, Jope RS. 2007. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3. J Biol Chem 282(23): 16989-17001.
27. Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G, Mayer D. 2005. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J Biol Chem 280(38): 33006-33014.
28. Meijer L, Flajolet M, Greengard P. 2004. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25(9): 471-480.
29. Nguyen MM, Dincer Z, Wade JR, Alur M, Michalak M, Defranco DB, Wang Z. 2009. Cytoplasmic localization of the androgen receptor is independent of calreticulin. Mol Cell Endocrinol 302(1): 65-72.
30. Perez DI, Conde S, Pérez C, Gil C, Simon D, Wandosell F, Moreno FJ, Gelpi JL, Luque FJ, Martinez A. 2009. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg Med Chem 17: 6914-6925.
31. Pierce AC, Haar E, Binch HM, Kay DP, Patel SR, Li P. 2005. CH. . .O and CH. . .N hydrogen bonds in ligand design: A novel quinazolin-4-ylthiazol-2- ylamine protein kinase inhibitor. J Med Chem 48:1278-1281.
32. Poukka H, Karvonen U, Yoshikawa N, Tanaka H, Palvimo JJ, Jänne OA. 2000. The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci 113(Pt 17): 2991-3001.
33. Rimler A, Culig Z, Levy-Rimler G, Lupowitz Z, Klocker H, Matzkin H, Bartsch G, Zisapel N. 2001. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate 49(2): 145-154.
34. Rimler A, Culig Z, Lupowitz Z, Zisapel N. 2002. Nuclear exclusion of the androgen receptor by melatonin. J Steroid Biochem Mol Biol 81(1): 77-84.
35. Rinnab L, Schütz SV, Jeannine Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler K-D, Cronauer MV. 2008. Inhibiton of glycogen-synthase kinase-3 (GSK) in androgen responsive prostate cancer cell lines - Are GSK-inhibitors therapeutically useful? Neoplasia 10(6): 624-633.
36. Rogatsky I, Waase CL, Garabedian MJ. 1998. Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3). Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. J Biol Chem 273:14315-14321.
37. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L. 2004. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279:19191-19200.
38. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, Wang Z. 2003. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem 278(43): 41998-42005. (Pubitemid 37310463)
39. Saporita AJ, Ai J, Wang Z. 2007. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67(5): 509-520.
40. Savory JG, Hsu B, Laquian IR, Giffin W, Reich T, Haché RJ, Lefebvre YA. 1999. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol 19(2): 1025-1037.
41. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. 2004. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11(3): 459-476. (Pubitemid 39331277)
42. Shank LC, Kelley JB, Gioeli D, Yang CS, Spencer A, Allison LA, Paschal BM. 2008. Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro. J Biol Chem 283(16): 10568-10580.
43. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS. 2009. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15(1): 39-47.
44. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG. 1999. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 161(4): 1229-1232.
45. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. 2002. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62(22): 6606-6614.
46. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK. 2000. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 14(8): 1162-1174.
47. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. 1996. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93(21): 11802-11807.
48. Wong HY, Burghoorn JA, Van Leeuwen M, De Ruiter PE, Schippers E, Blok LJ, Li KW, Dekker HL, De Jong L, Trapman J, Grootegoed JA, Brinkmann AO. 2004. Phosphorylation of androgen receptor isoforms. Biochem J 383:267-276.
49. Woodgett JR. 1990. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9:2431-2438.
50. Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM. 1994. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal-and carboxyl-terminal sequences. J Biol Chem 269(18): 13115-13123.